Beyond Krabbe's disease: The potential contribution of galactosylceramidase deficiency to neuronal vulnerability in late-onset synucleinopathies

Journal of Neuroscience Research

Volumn 94, Issue 11, 2016, Pages 1328-1332

  Marshall, Michael S ^a   Bongarzone, Ernesto R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alzheimer's disease; dementia; Krabbe's disease; lysosomal deficiency; neuronal degeneration; Parkinson's disease; psychosine; synaptic failure; synuclein

Indexed keywords

GALACTOSYLCERAMIDASE; LIPID; PROTEIN AGGREGATE; SYNUCLEIN;

AUTOPHAGY; CELL FUNCTION; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; GENETIC PREDISPOSITION; GLOBOID CELL LEUKODYSTROPHY; HUMAN; LATE ONSET DISORDER; LATE ONSET SYNUCLEINOPATHY; LIPID MEMBRANE; LYSOSOME; MOLECULAR INTERACTION; NERVE CELL; NOTE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFECT; SYNAPSE;

EID: 84990246154     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23751     Document Type: Note

References (23)

1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197–211.
2. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. 2010. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329:1663–1667.
3. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL. 2002. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22:8797–8807.
4. Calo L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M. 2016. Synaptic failure and alpha-synuclein. Mov Disord 31:169–177.
5. Castelvetri LC, Givogri MI, Zhu HL, Smith B, Lopez-Rosas A, Qiu X, van Breemen R, Bongarzone ER. 2011. Axonopathy is a compounding factor in the pathogenesis of Krabbe disease. Acta Neuropathol 122:35–48.
6. Castelvetri LC, Givogri MI, Hebert A, Smith B, Song Y, Kaminska A, Lopez-Rosas A, Morfini G, Pigino G, Sands M, Brady ST, Bongarzone ER. 2013. The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3β and deregulation of molecular motors. J Neurosci 33:10048–10056.
7. De Gasperi R, Gama Sosa MA, Sartorato EL, Battistini S, MacFarlane H, Gusella JF, Krivit W, Kolodny EH. 1996. Molecular heterogeneity of late-onset forms of globoid-cell leukodystrophy. Am J Hum Genet 59:1233–1242.
8. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. 2004. Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 24:6715–6723.
9. Haughey NJ. 2010. Sphingolipids in neurodegeneration. Neuromol Med 12:301–305.
10. Keilani S, Lun Y, Stevens AC, Williams HN, Sjoberg ER, Khanna R, Valenzano KJ, Checler F, Buxbaum JD, Yanagisawa K, Lockhart DJ, Wustman BA, Gandy S. 2012. Lysosomal dysfunction in a mouse model of Sandhoff disease leads to accumulation of ganglioside-bound amyloid-beta peptide. J Neurosci 32:5223–5236.
11. Maroteaux L, Campanelli JT, Scheller RH. 1988. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8:2804–2815.
12. Marsh SE, Blurton-Jones M. 2012. Examining the mechanisms that link beta-amyloid and alpha-synuclein pathologies. Alzheimers Res Ther 4:11.
13. Martinez Z, Zhu M, Han SB, Fink AL. 2007. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 46:1868–1877.
14. Mattsson N, Olsson M, Gustavsson MK, Kosicek M, Malnar M, Mansson JE, Blomqvist M, Gobom J, Andreasson U, Brinkmalm G, Vite C, Hecimovic S, Hastings C, Blennow K, Zetterberg H, Portelius E. 2012. Amyloid-beta metabolism in Niemann-Pick C disease models and patients. Metab Brain Dis 27:573–585.
15. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. 2011. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37–52.
16. Ohmi K, Kudo LC, Ryazantsev S, Zhao HZ, Karsten SL, Neufeld EF. 2009. Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy. Proc Natl Acad Sci U S A 106:8332–8337.
17. Ribbens JJ, Moser AB, Hubbard WC, Bongarzone ER, Maegawa GH. 2014. Characterization and application of a disease-cell model for a neurodegenerative lysosomal disease. Mol Genet Metab 111:172–183.
18. Scott D, Roy S. 2012. alpha-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci 32:10129–10135.
19. Shachar T, Lo Bianco C, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH. 2011. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord 26:1593–1604.
20. Smith BR, Santos MB, Marshall MS, Cantuti-Castelvetri L, Lopez-Rosas A, Li G, van Breemen R, Claycomb KI, Gallea JI, Celej SM, Crocker S, Givogri MI, Bongarzone ER. 2014. Neuronal inclusions of α-synuclein contribute to the pathogenesis of Krabbe disease. J Pathol 232:509–521.
21. Visanji NP, Brooks PL, Hazrati LN, Lang AE. 2013. The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol Commun 1:2.
22. White AB, Givogri MI, Lopez-Rosas A, Cao H, van Breemen R, Thinakaran G, Bongarzone ER. 2009. Psychosine accumulates in membrane microdomains in the brain of krabbe patients, disrupting the raft architecture. J Neurosci 29:6068–6077.
23. Xilouri M, Brekk OR, Stefanis L. 2016. Autophagy and alpha-synuclein: relevance to Parkinson's disease and related synucleopathies. Mov Disord 31:178–192.